Our clinical trials of tildacerfont in adults with classic CAH, CAHmelia 203 and CAHmelia 204, are open for screening | LEARN MORE

About Spruce Biosciences

Spruce is committed to transforming the lives of patients living with rare endocrine disorders. Spruce’s wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult patients with classic congenital adrenal hyperplasia (CAH).

Learn More

Spruce is proud to join the global community in support of Rare Disease Day to showcase our unwavering dedication to bettering the lives of patients, families and caregivers impacted by rare endocrine disorders.

Challenges of Classic CAH Treatment

Patients and physicians are faced with the difficult choice between the detrimental effects of chronically high adrenal androgen levels or excessive doses of glucocorticoids. This dilemma has persisted for approximately 50 years.

Detrimental effects of chronically high adrenal androgen levels
Harmful consequences of excessive, lifelong glucocorticoid use